Biopharma AI
By
AlphaMeld AI and VedTechBio: Can Their AI Alliance Cut Discovery Timelines by 50% Across 3 Liver & Metabolic Programs?
Key Highlights Strategic Alliance to Bridge AI Discovery and Translational ExecutionAlphaMeld Corporation, a global leader in AI-native drug…
Can This AI-Driven Biotech Duo Cut Biologic Development Timelines by 40%? Axio and Likarda Bet on It
Key Highlights • AI-driven protein production from Axio BioPharma integrates with Likarda’s Core-Shell Spherification® (CSS®) delivery platform to…
How Xsolis’ AI-Driven Dragonfly Clinched the 2025 MedTech’s ‘Clinical Efficiency Innovation Award’? Targets the $1 Trillion U.S. Healthcare Waste Crisis Clinical Efficiency Innovation Award
Key Highlights Xsolis Sets New Standard in AI-Powered Clinical EfficiencyTennessee-based AI tech firm Xsolis has won top honors…
Can MIT and Recursion’s New AI Model Boltz-2 Slash Drug Discovery Time by 1000x and Outperform AlphaFold3?
Key Takeaways• Boltz-2 delivers AI-driven binding affinity predictions 1000x faster than traditional free energy methods—dramatically accelerating virtual screening…
How Is XtalPi’s Expanded Collaboration With Pfizer Set to Transform AI-Driven Small Molecule Drug Discovery?
Key Takeaways Empowering Next-Gen AI Platforms for Predictive Drug DiscoveryXtalPi and Pfizer have extended their strategic partnership to…
Is AI-Engineered HMBD-002 the Next Big Immunotherapy? Hummingbird Bioscience Signs $290M Global Licensing Deal with Percheron Therapeutics
Key Highlights Strategic Global Licensing Deal Hummingbird Bioscience has signed a worldwide licensing agreement with Percheron Therapeutics for…
